NASDAQ:CLDX Celldex Therapeutics Q4 2024 Earnings Report $23.35 +0.13 (+0.56%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$23.00 -0.35 (-1.50%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Celldex Therapeutics EPS ResultsActual EPS-$0.71Consensus EPS -$0.73Beat/MissBeat by +$0.02One Year Ago EPSN/ACelldex Therapeutics Revenue ResultsActual Revenue$1.18 millionExpected Revenue$1.25 millionBeat/MissMissed by -$72.00 thousandYoY Revenue GrowthN/ACelldex Therapeutics Announcement DetailsQuarterQ4 2024Date2/27/2025TimeBefore Market OpensConference Call DateThursday, February 27, 2025Conference Call Time9:30AM ETUpcoming EarningsCelldex Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Celldex Therapeutics Earnings HeadlinesCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $50.11 Average PT from AnalystsJuly 19, 2025 | americanbankingnews.comCLDX Celldex Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthright” — a $150 trillion wealth vault that’s remained untouched for over a century. Jim Rickards believes President Trump is about to unleash it — and investors who move first could come out on top. The full story is now available. | Paradigm Press (Ad)Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025June 16, 2025 | morningstar.comMCelldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challengesJune 15, 2025 | investing.comCelldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025June 14, 2025 | globenewswire.comSee More Celldex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email. Email Address About Celldex TherapeuticsCelldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.View Celldex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Why Freeport-McMoRan Stock May Hit a New High After Earnings BeatMicrosoft’s AI Bet Faces a Major Test This Earnings SeasonAmazon Stock Rally Hits New Highs: Buy Into Earnings?TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your Portfolio Upcoming Earnings AstraZeneca (7/29/2025)Booking (7/29/2025)Mondelez International (7/29/2025)PayPal (7/29/2025)Starbucks (7/29/2025)American Tower (7/29/2025)America Movil (7/29/2025)Boeing (7/29/2025)Barclays (7/29/2025)Carrier Global (7/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
